Um diesen Inhalt von Vimeo zu sehen, müssen sie Ihre Zustimmung geben, dass auf Ihrem Gerät Cookies von Vimeo gespeichert werden dürfen.

Inhalte im Video:

00:00

Overall survival update of the FLAURA trial: osimertinib improved OS in treatment-naïve patients versus an older-generation TKI significantly.

01:50

Even in the trial situation that took place in the best institutions, only 30% of patients in the standard arm could cross over to osimertinib: Therefore, first-line osimertinib is the new standard of care.

03:04

PROMISE-meso: First phase III randomized trial investigating immunotherapy in mesothelioma as a 2nd line treatment. After several promising trials on immunotherapy in mesothelioma, pembrolizumab was not superior to standard chemotherapy.

Interview mit:

Prof. Solange Peters, MD, PhD

Interview von:

Dr. Birgit Beermann

Produziert von:

Mag. Oliver Eberhardt

Dr. Birgit Beermann

2. Okt. 2019Breakfast Brief

ESMO 2019: “In lung cancer, you have to start with the best treatment first”

Prof. Solange Peters, MD, PhD, CHUV Lausanne, about the OS update of the FLAURA trial and disappointing news for immunotherapy in mesothelioma with the PROMISE-meso trial.

Abstracts in this interview:

Ramalingam S et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. #LBA5_PR
Popat S et al. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. # LBA91_PR

ESMO Congress 2019